Guselkumab in Psoriatic Arthritis: Therapeutic Impact on Axial and Peripheral Involvement-Monocentric Real-World Evidence.

Clinimetric Evaluation The results, presented in Table 3 below, indicate that all clinimetric measures showed highly significant improvements across the entire follow-up period and in pairwise comparisons between successive time points, except for ASDAS scores at 6 and 12 months, where no significant difference was observed.

also in 132,142 other papers